Skip to content

Evaluating the Need for Restrictions After Hot Snare Polypectomy and Endoscopic Mucosal Resection

Evaluating the Need for Restrictions After Hot Snare Polypectomy and Endoscopic Mucosal Resection - Evaluating the Need for Restrictions After HSP and EMR

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000057781
Enrollment
200
Registered
2025-05-05
Start date
2023-05-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colonic polyps

Interventions

Sponsors

NTT Medical Center Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age 20 years or older at the time of enrollment. ECOG performance status of 0 or 1. Laboratory values within 30 days prior to enrollment meet all of the following (no blood transfusion within 14 days prior to the labs used for enrollment): ??. Hemoglobin equal to or greater than 9 g/dL ??. Platelet count equal to or greater than 100000/mm3 ??. AST and ALT less than or equal to 100 IU/L ??. Serum creatinine less than or equal to 2.0 mg/dL Ability to be followed for 30 days post-procedure. Written informed consent obtained for participation in the study. An adult cohabitant must be present in the participant's household, and the participant must be able to visit the hospital within 2 hours if necessary.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: History of endoscopic treatment for lower gastrointestinal lesions within 30 days prior to enrollment. Planned endoscopic treatment for the lower gastrointestinal tract within 30 days after enrollment. Women who are pregnant, possibly pregnant, or breastfeeding. Patients with psychiatric disorders that impair their ability to fully understand the study. History of myocardial infarction or unstable angina within the past 3 months. Known coagulation disorders. Active bacterial or fungal infections, defined as a body temperature of 38.5 degrees Celsius or higher with radiological or microbiological evidence of infection. Respiratory diseases requiring continuous oxygen therapy. Patients undergoing dialysis. Uncontrolled hypertension. Any case deemed unsuitable for participation in the study by the attending physician. Sporadic localized tumors or dysplasia-associated lesions or masses (DALMs) associated with chronic inflammation such as ulcerative colitis. Lesions with local residual disease after previous endoscopic resection or those located at postoperative anastomotic sites.

Design outcomes

Primary

MeasureTime frame
incidence of adverse events

Secondary

MeasureTime frame
Risk factors for the development of adverse events

Countries

Japan

Contacts

Public ContactShinya Nagae

NTT Medical Center Tokyo Department of Gastrointestinal Endoscopy

shinyanagae1993@gmail.com03-3448-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026